# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-25-002045
**Filing Date:** 2025-6
**Character Count:** 9478
**Document Hash:** 7f53afc728fe948a8370c2622cf637ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-002045.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001178913-25-002045

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250603

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42253
- **FILM NUMBER:** 251019381

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

?xml version='1.0' encoding='ASCII'?

------

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **June 3, 2025 (May 28, 2025)**

**Silexion Therapeutics Corp**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands**<br>| **001-42253**<br>| **N/A** |
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer |
| of incorporation) |  | Identification No.) <br>|

---

---

| | |
|:---|:---|
| **12 Abba Hillel Road**<br>**Ramat-Gan, Israel**<br>| **5250606**<br>|
| (Address of principal executive offices) | (Zip Code) <br>|

---

**+972-3-7564999**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Ordinary Shares, par value $0.0009 per share**<br>| **SLXN** | **The Nasdaq Stock Market LLC**<br>|
| **Warrants exercisable for Ordinary Shares at an exercise price of $103.50 per share**<br>| **SLXNW**<br>| **The Nasdaq Stock Market LLC**<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

#### Item 8.01 Other Events.

#### Appeal of Nasdaq Delisting Notice; Continued Trading of Securities
On May 28, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company (the "**Company**", "**we**", "**us**" or "**our**") requested a hearing related to the delisting notice that the Company had received from the Nasdaq Listing Qualifications Department on May 22, 2025 in respect of two listing deficiencies. As a result of our hearing request, the delisting process in respect of the Company's ordinary shares and warrants has been stayed, at least until the date of the hearing, and our securities will therefore continue trading on the Nasdaq Global Market under the existing symbols "SLXN" and "SLXNW", respectively.

As we had previously reported (initially under "*Market Value-Related Deficiencies*" in Item 3.01 of our Current Report on Form 8-K filed with the Securities and Exchange Commission (the "**SEC**") on November 22, 2024), the two listing deficiencies, for which we had received two letters from the Nasdaq Listing Qualifications Department on November 19, 2024, relate to our non-compliance with Nasdaq Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C), which require a company such as ours whose securities are listed on the Nasdaq Global Market under the "Market Value Standard" to maintain a minimum Market Value of Listed Securities (an "**MVLS**") of $50,000,000 and a minimum Market Value of Publicly Held Shares (an "**MVPHS**") of $15,000,000 for continued listing on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c)(3)(C), we had been given a 180-day period, ending on May 19, 2025, to rectify the deficiencies, but were unable to do so during that period.

As also previously disclosed in our Current Report on Form 8-K filed with the SEC on May 23, 2025, as part of our strategy for our appeal, we intend to apply to transfer the listing of our securities to the Nasdaq Capital Market, subject to our meeting the Equity Standard for continued listing on that market, which requires us to have, among other things, at least $2.5 million of shareholders' equity. We may also request from the Nasdaq Hearings Panel additional time to meet that Equity Standard. There can be no assurance, however, that our hearing and request for transfer will be successful or that we will successfully comply with that Equity Standard for listing on the Nasdaq Capital Market within any extension period that may be granted by the Nasdaq Hearings Panel.

#### Forward-Looking Statements
This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" and other similar expressions are intended to identify forward-looking statements. Those statements include those related to: the Company's appeal of Nasdaq's delisting determination and the prospective hearing that will be held at the Nasdaq Hearings Panel on June 26, 2025 in respect of the Company's appeal; the Company's ability to transfer the listing of its securities to the Nasdaq Capital Market; the Company's ability to have at least $2.5 million of shareholders' equity and meet the Equity Standard for continued listing on the Nasdaq Capital Market and/or to be granted additional time to meet that listing standard; and all other statements that are not historical facts. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Current Report on Form 8-K, including but not limited to, that: the Company may not be successful at the hearing related to the delisting notice received by the Company from the Nasdaq Listing Qualifications Department; and the Company may not be granted additional time to achieve or maintain at least $2.5 million of shareholders' equity and meet the Equity Standard of the Nasdaq Capital Market to enable the transfer of the listing of its securities to that market. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. That filing identifies and addresses other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise those forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SILEXION THERAPEUTICS CORP** | **SILEXION THERAPEUTICS CORP** |
| Date: June 3, 2025 | By: | /s/ Ilan Hadar |
|  | Name: | Ilan Hadar |
|  | Title: | Chief Executive Officer |

---

------